Therapy News and Research

RSS

New study following 12,574 individuals over the course of three years of HAART

Although clinical progression to AIDS of patients infected with Human immunodeficiency virus (HIV) has declined since the introduction of Highly Active Antiretroviral Therapy (HAART), there is little data on the changes in incidence of AIDS-defining events during the first few years of therapy.

28 Feb 2005

Hospital admission medication errors common and potentially harmful

A medication use history is an integral part of the hospital admission process, but errors in the history may result in failure to detect drug-related problems or lead to interrupted or inappropriate drug therapy during hospitalization, according to background information in the article. Earlier studies suggest that these errors are a potentially serious safety issue.

28 Feb 2005

$Primary reason to diagnose and treat osteoporosis is to prevent bone fractures$

Primary reason to diagnose and treat osteoporosis is to prevent bone fractures

In an editorial in the February 28 issue of Archives of Internal Medicine, Alan L. Buchman, M.D., M.P.H., of the Feinberg School of Medicine at Northwestern University, Chicago, writes that the primary reason to diagnose and treat osteoporosis is to prevent bone fractures.

28 Feb 2005

People with osteoporosis should be screened for celiac disease

Results of a new study suggest that the higher prevalence of celiac disease in individuals with osteoporosis than in the general population may justify screening of patients with osteoporosis for celiac disease, according to an article in the February 28 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

28 Feb 2005

Hormone therapy for prostate cancer can affect men's thinking

Androgen-deprivation therapy (AD), an effective therapy in the treatment of prostate cancer reduces levels of testosterone (a tumor stimulant), and estradiol, a form of estrogen, in men. These are known to be important in neurological development and play a particularly important role in the cognitive areas of learning and memory.

28 Feb 2005

Youth with HIV take more risks after new meds introduced

Teens with HIV are having more risky sex with more partners than their counterparts did in the years before powerful new medications for HIV were introduced in 1996, according to a new report in the American Journal of Health Behavior.

28 Feb 2005

European approval of Pegasys for the treatment of chronic hepatitis B

The approval is granted for both types of the disease – HBeAg-positive and HBeAg-negative chronic hepatitis B. Pegasys offers the hope of a treatment-free life for thousands of people with chronic hepatitis B as this innovative drug has been shown to achieve lasting remission for a significant proportion of patients.

27 Feb 2005

Scientific rationale behind the use of antiretroviral therapy

Johns Hopkins researcher and infectious disease specialist Robert Siliciano, M.D., Ph.D., will provide an update on the scientific rationale behind the use of antiretroviral therapy, focusing on the mechanisms that allow life-long persistence of HIV even in patients on potent medication.

27 Feb 2005

Dual testing better for monitoring new cases of HIV

Johns Hopkins researchers will present results showing that tighter, dual testing standards work better for accurately distinguishing between new and old cases of HIV.

27 Feb 2005

NIH awards grant to explore causal relationship between epoetin dose and survival of hemodialysis patients

The National Institutes of Health, National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) has awarded a two-year grant to the Medical Technology and Practice Patterns Institute (MTPPI) in collaboration with Harvard School of Public Health (HSPH) to explore the causal relationship between epoetin dose and survival of hemodialysis patients receiving this therapy.

27 Feb 2005

Genzyme begins gene transfer trial for peripheral arterial disease

Genzyme Corporation announced today that the first patient has been treated in a new phase 2 clinical trial examining the safety and effectiveness of locally delivered gene transfer for patients with peripheral arterial disease.

24 Feb 2005

Dental therapy that regenerates the tooth enamel rather than drilling

Unlike skins or bones, the tooth enamel, which forms the hard surface of a tooth, does not regenerate itself once damaged. Therefore, the conventional dental treatment includes drilling of the decayed part of a tooth and filling the hole with resin or metal alloy dental materials.

24 Feb 2005

Trial results on the use of recombinant activated factor VII in acute intracerebral haemorrhage

The New England Journal of Medicine (NEJM) today reports positive results from the recently completed clinical trial of recombinant activated factor VII (NovoSeven/rFVIIa) in intracerebral haemorrhage (ICH).

24 Feb 2005

Common clinical problem, Rosacea

A number of clinical symptoms and signs are included under the broad group Rosacea. Facial flushing, the appearance of broken blood vessels and persistent redness of the face, eruption of inflamed spots & pimples, on the face and thickening of the sebaceous glands of the nose, with swelling & congestion in that area.

24 Feb 2005

FDA approves Atacand (candesartan cilexetil) for the treatment of heart failure

AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved its angiotensin receptor blocker (ARB) Atacand (candesartan cilexetil) Tablets for the treatment of heart failure (NYHA class II-IV and ejection fraction less than or equal to 40%) to reduce the risk of death from cardiovascular causes and reduce hospitalizations for heart failure.

23 Feb 2005

MRSA superbug on the run from Sussex scientist

A groundbreaking new treatment to combat the hospital killer bug MRSA, which is estimated to cause up to 5,000 deaths a year in Britain, is being developed by a University of Sussex scientist.

23 Feb 2005

Feverfew or Bachelor's Button, kills human leukemia stem cells like no other single therapy

A daisy-like plant known as Feverfew or Bachelor's Button, a traditional remedy for reducing fevers and a treatment for nervousness, hysteria and low spirits, is the source of an agent that kills human leukemia stem cells like no other single therapy

23 Feb 2005

Exercise therapy can improve muscle strength in people with multiple sclerosis

Exercise therapy also improved the mood of MS patients in exercise therapy programs, compared to patients who did not participate in the therapy. The researchers did not find any evidence that exercise therapy affected patients’ fatigue or their sense of how ill they were.

22 Feb 2005

Benitec announces AIDS collaboration

Benitec today announced a collaboration with City of Hope (based in Duarte California) to develop a novel T-cell based therapy for AIDS patients.

22 Feb 2005

Why some lung cancers stop responding to the drugs erlotinib (Tarceva) and gefitinib (Iressa)

Researchers at Memorial Sloan-Kettering Cancer Center (MSKCC) have found an explanation for why some lung cancers stop responding to the drugs erlotinib (Tarceva) and gefitinib (Iressa).

22 Feb 2005